No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation.
Thomas NeumannLaila SchneidewindThomas ThieleDaniel PinkMeike SchulzeChristian SchmidtWilliam KrügerPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2017)
We saw no indication of increased infections rates when using low-dose alemtuzumab as GvHD prophylaxis before allogeneic stem cell transplantation in this retrospective analysis.